CDK4 and cancer: These findings are highly topical, given that existing strategies targeting aberrant cell-cycle regulation such as CDK4/-6 inhibitors, which have become the standard of care for metastatic hormone receptor–positive cancers, are limited by the development of resistance (3, 78, 79) and may be less effective against luminal B–like tumors compared with luminal A types (80, 81).